1. Comparison between groups
Anthropometric parameters and GH dose after 2 yr of GH therapy in patients with CP (n=183) and NFPA (n=209)
Treatment effects after 2 yr (chance compared to baseline)a pb
No.
Mean ± SD
Compared to baseline
Comparison between groups
GH dose (mg/d)
Male CP
NFPA
Female 98 97 81
101
0.39 ± 0.21
0.39 ± 0.22
0.47 ± 0.26
0.49 ± 0.22 NA
0.90
0.10
Weight (kg)
Male CP
NFPA
Female 96
101 87
108
2.50 ± 8.15
0.63 ± 5.96
3.36 ± 6.72
-0.31 ± 6.43
0.01
0.10
0.0001
0.88
0.36
0.001
Abbildung mod. nach Verhelst, 2005

2. Comparison between groups
Anthropometric parameters and GH dose after 2 yr of GH therapy in patients with CP (n=183) and NFPA (n=209)
Treatment effects after 2 yr (chance compared to baseline)a pb
No.
Mean ± SD
Compared to baseline
Comparison between groups
BMI (kg/m2)
Male CP
NFPA
Female 88 91 82 97
0.73 ± 2.11
0.17 ± 1.89
1.33 ± 2.68
-0.23 ± 2.41
0.004
0.20
0.0001
0.66
0.19
0.0002
Waist (cm)
Male CP
NFPA
Female 64 71 63 78
-1.27 ± 5.64
-3.03 ± 5.23
2.45 ± 6.00
-2.06 ± 7.16
0.11
0.0001
0.003
0.02
0.06
0.0003
Abbildung mod. nach Verhelst, 2005

3. Comparison between groups
Anthropometric parameters and GH dose after 2 yr of GH therapy in patients with CP (n=183) and NFPA (n=209)
Treatment effects after 2 yr (chance compared to baseline)a pb
No.
Mean ± SD
Compared to baseline
Comparison between groups
WHR
Male CP
NFPA
Female 64 71 63 78
-0.02 ± 0.06
-0.02 ± 0.04
0.01 ± 0.05
-0.01 ± 0.06
0.02
0.0001
0.13
0.17
0.45
0.04
Fat mass (kg)c
Male CP
NFPA
Female 24 21 22 20
-0.87 ± 6.07
-2.48 ± 6.72
2.36 ± 6.63
-3.02 ± 5.75
0.47
0.07
0.22
0.04
0.40
0.02
Abbildung mod. nach Verhelst, 2005

4. Comparison between groups
Anthropometric parameters and GH dose after 2 yr of GH therapy in patients with CP (n=183) and NFPA (n=209)
Treatment effects after 2 yr (chance compared to baseline)a pb
No.
Mean ± SD
Compared to baseline
Comparison between groups
Fat-free mass (kg)c
Male CP
NFPA
Female 24 21 20
3.10 ± 5.09
3.80 ± 6.30
2.10 ± 4.61
0.33 ± 3.31
0.007
0.01
0.03
0.60
0.69
0.17
BMI, Body mass index; NA, not applicable because no patient was taking GH at baseline
a Information missing in several patients in both groups.
b Wilcoxon rank-sum test (nonnormal distributet values) or t test (normal distributet values). c Only results from BIA.
Abbildung mod. nach Verhelst, 2005